MK0686

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neuralgia, Postherpetic

Conditions

Neuralgia, Postherpetic

Trial Timeline

Dec 1, 2005 → Aug 1, 2006

NCT ID

NCT00282763

About MK0686

MK0686 is a phase 2 stage product being developed by Merck for Neuralgia, Postherpetic. The current trial status is terminated. This product is registered under clinical trial identifier NCT00282763. Target conditions include Neuralgia, Postherpetic.

What happened to similar drugs?

8 of 18 similar drugs in Neuralgia, Postherpetic were approved

Approved (8) Terminated (3) Active (8)

✅QUTENZAAstellas PharmaApproved

✅GalcanezumabEli LillyApproved

✅Etoricoxib + PlaceboMerckApproved

✅pregabalinPfizerApproved

✅Lyrica (pregabalin) + PlaceboPfizerApproved

✅pregabalin + PlaceboPfizerApproved

✅PregabalinPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00282763	Phase 2	Terminated	Dec 1, 2005	Aug 1, 2006	Neuralgia, Postherpetic
NCT00296569	Phase 2	Completed	Sep 1, 2005	May 1, 2006	Osteoarthritis
NCT00533403	Phase 2	Completed	Jul 1, 2004	Nov 1, 2004	Pain, Postoperative

Competing Products

20 competing products in Neuralgia, Postherpetic

See all competitors

Product	Company	Stage	Hype Score
Placebo + DS-5565	Daiichi Sankyo	Pre-clinical	26
QUTENZA	Astellas Pharma	Approved	43
ASP8477 + Placebo	Astellas Pharma	Phase 2	35
E2007 (perampanel) + Placebo	Eisai	Phase 2	35
E2007	Eisai	Phase 2/3	38
KHK6188 + Placebo	Kyowa Kirin	Phase 2	35
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Galcanezumab	Eli Lilly	Approved	43
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day	Jiangsu Hengrui Medicine	Phase 3	36
ABT-894 + ABT-894 + ABT-894 + placebo + Duloxetine	AbbVie	Phase 2	35
MK-8291 + Placebo	Merck	Phase 1	29
Etoricoxib + Placebo	Merck	Approved	39
Cetuximab + Placebo	Merck	Phase 2	35
ADL5747 + Placebo + Pregabalin	Merck	Phase 2	27
MK0759	Merck	Phase 2	27
Comparator: pregabalin + Comparator: Placebo (unspecified)	Merck	Phase 1	29
EMA401 + Placebo	Novartis	Phase 2	27
pregabalin	Pfizer	Approved	43
Lyrica (pregabalin) + Placebo	Pfizer	Approved	43
2-weeks placebo then gabapentin + 1-week placebo then gabapentin	Pfizer	Pre-clinical	26